Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma

References

• Stupp R, Mason WP, van Den Bent MJ et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. Epub 2005/03/11. PubMed PMID: 15758009.
   PubMed Web of Science ®Google Scholar
• Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–64; discussion 264–6. Epub 2008/05/23. PubMed PMID: 18496181.
   Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. Epub 2015/02/11. PubMed PMID: 25667295; PubMed Central PMCID: PMCPMC5089162 are found at the end of this article.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. Epub 2015/12/30. PubMed PMID: 26712084.
   PubMed Web of Science ®Google Scholar
• Wolchok JD. PD-1 Blockers. Cell. 2015;162(5):937. Epub 2015/09/01. PubMed PMID: 26317459.
   PubMed Web of Science ®Google Scholar
• Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol2018;62:29–39. Epub 2018/ 07/11. PubMed PMID: 29990692.
   PubMed Web of Science ®Google Scholar
• Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356(6370):607–609. Epub 1992/ 04/16. PubMed PMID: 1313950.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. Epub 2002/09/10. PubMed PMID: 12218188; PubMed Central PMCID: PMCPMC129438.
   PubMed Web of Science ®Google Scholar
• Maxwell R, Jackson CM, Lim M. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Curr Treat Options Oncol. 2017 Epub 2017/08/09. doi: 10.1007/s11864-017-0492-y. PubMed PMID: 28785997;18(8):51.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–e51. Epub 2016/12/08. PubMed PMID: 27924752; PubMed Central PMCID: PMCPMC5702534.
   PubMed Web of Science ®Google Scholar
• Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206–2211. Epub 2016/ 03/24. PubMed PMID: 27001570.
   PubMed Web of Science ®Google Scholar
• Johanns TM, Miller CA, Dorward IG, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline pole deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–1236. Epub 2016/11/04. PubMed PMID: 27683556; PubMed Central PMCID: PMCPMC5140283.
   PubMed Web of Science ®Google Scholar
• Orpilla J, Mochizuki A, Reynoso J, et al. ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA. Neuro Oncol. 2018;20(suppl_6):vi6–vi.
   Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730. PubMed PMID: 30134131.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–983. Epub 2016/ 06/09. PubMed PMID: 27267608; PubMed Central PMCID: PMCPMC5526047.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Gokhale PC, Klein SR, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res. 2016;4(2):124–135. Epub 2015/ 11/08. PubMed PMID: 26546453.
   PubMed Web of Science ®Google Scholar
• Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13(7):2158–2167. Epub 2007/ 04/04. PubMed PMID: 17404100.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. Epub 2016/08/24. PubMed PMID: 27549193; PubMed Central PMCID: PMCPMC4993001.
   PubMed Web of Science ®Google Scholar
• Genoud V, Marinari E, Nikolaev SI, et al. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. OncoImmunology. 2018;7(12):e1501137.
   PubMed Web of Science ®Google Scholar
• Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948 Epub 1948/02/01. PubMed PMID: 18865105; PubMed Central PMCID: PMCPMC2073079.;29(1):58–69.
   PubMedGoogle Scholar
• Canessa A, Del Bono V, Miletich F, et al. Serum cytokines in toxoplasmosis: increased levels of interferon-gamma in immunocompetent patients with lymphadenopathy but not in AIDS patients with encephalitis. J Infect Dis. 1992;165(6): 1168–1170. Epub 1992/ 06/01.PubMed PMID: 1583343.
   PubMed Web of Science ®Google Scholar
• Woodroofe MN, Bellamy AS, Feldmann M, et al. Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. J Neurol Sci. 1986;74(2–3):135–152. Epub 1986/07/01. PubMed PMID: 3488371.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ. et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015; 523(7560): 337–341. Epub 2015/ 06/02. PubMed PMID: 26030524; PubMed Central PMCID: PMCPMC4506234.
   PubMed Web of Science ®Google Scholar
• Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev2006;213:48–65. Epub 2006/ 09/16. doi:. PubMed PMID: 16972896; PubMed Central PMCID: PMCPMC2633103.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Venur VA, Preusser M, et al., Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book. 2016(36):e116–e22. doi: 10.1200/edbk_100005. PubMed PMID: 30372337.
   PubMedGoogle Scholar
• Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–88. Epub 2006/ 12/13. PubMed PMID: 17159987.
   PubMed Web of Science ®Google Scholar
• Heiland DH, Haaker G, Delev D, et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget. 2017;8(26):42214–42225. Epub 2017/02/09. PubMed PMID: 28178682; PubMed Central PMCID: PMCPMC5522061.
   PubMedGoogle Scholar
• Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847–856. Epub 2015/02/20. 10.1158/1535-7163.MCT-14-0983. PubMed PMID: 25695955.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. Epub 2013/ 06/19. PubMed PMID: 23770567; PubMed Central PMCID: PMCPMC3919509.
   PubMed Web of Science ®Google Scholar
• Yeung JT, Hamilton RL, Ohnishi K, et al. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res. 2013;19(7):1816–1826. Epub 2013/02/13. 10.1158/1078-0432.CCR-12-2861. PubMed PMID: 23401227; PubMed Central PMCID: PMCPMC3618546.
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20(20):5290–5301. Epub 2014/04/03. 10.1158/1078-0432.CCR-14-0514. PubMed PMID: 24691018; PubMed Central PMCID: PMCPMC4182350.
   PubMed Web of Science ®Google Scholar
• Groot JFD, Penas-Prado M, Mandel JJ, et al. Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. J Clin Oncol. 2018;36(15_suppl):2008.
   PubMedGoogle Scholar
• Gabrusiewicz K, Rodriguez B, Wei J, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2). Epub 2016/03/15. doi: 10.1172/jci.insight.85841. PubMed PMID: 26973881; PubMed Central PMCID: PMCPMC4784261.
   PubMed Web of Science ®Google Scholar
• Stevens A, Kloter I, Roggendorf W. Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer. 1988 Epub 1988/02/15. PubMed PMID: 3338036;61(4):738–743.
   PubMed Web of Science ®Google Scholar
• Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg. 2009 Epub 2009/02/10. 10.3171/2008.7.JNS08475. PubMed PMID: 19199469; PubMed Central PMCID: PMCPMC3064468;110(3):572–582.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15–24. Epub 2008/06/17. doi:. PubMed PMID: 18553315.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Abou-Ghazal M, Reina-Ortiz C. et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008; 14(16): 5166–5172. Epub 2008/ 08/14. PubMed PMID: 18698034.
   PubMed Web of Science ®Google Scholar
• Badie B, Bartley B, Schartner J. Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol. 2002;133(1–2):39–45. Epub 2002/11/26. PubMed PMID: 12446006.
   PubMed Web of Science ®Google Scholar
• Schartner JM, Hagar AR, Van Handel M, et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005;51(4):279–285. Epub 2005/04/09. PubMed PMID: 15818597.
   PubMed Web of Science ®Google Scholar
• Didenko VV, Ngo HN, Minchew C, et al. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg. 2002;96(3):580–584. Epub 2002/ 03/09. PubMed PMID: 11883844; PubMed Central PMCID: PMCPMC1853267.
   PubMed Web of Science ®Google Scholar
• Wischhusen J, Friese MA, Mittelbronn M, et al. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol. 2005;64(6): 523–528. Epub 2005/ 06/28.PubMed PMID: 15977644.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002;168(9):4772–4780. Epub 2002/ 04/24.PubMed PMID: 11971028.
   PubMed Web of Science ®Google Scholar
• Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989;143(10):3222–3229. Epub 1989/11/15. PubMed PMID: 2809198.
   PubMed Web of Science ®Google Scholar
• Huettner C, Czub S, Kerkau S, et al. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 1997;17(5A): 3217–3224. Epub 1997/ 12/31.PubMed PMID: 9413151.
   PubMed Web of Science ®Google Scholar
• Lauro GM, Di Lorenzo N, Grossi M, et al. Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol. 1986;69(3–4): 278–282. Epub 1986/01/01. PubMed PMID: 3485879.
   PubMed Web of Science ®Google Scholar
• Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–442. Epub 2018/04/13. PubMed PMID: 29643471.
   PubMed Web of Science ®Google Scholar
• Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010;12(7):631–644. Epub 2010/ 02/25. PubMed PMID: 20179016; PubMed Central PMCID: PMCPMC2940665.
   PubMed Web of Science ®Google Scholar
• Bloch O, Crane CA, Kaur R, et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013 Epub 2013/04/25. 10.1158/1078-0432.CCR-12-3314. PubMed PMID: 23613317; PubMed Central PMCID: PMCPMC3742575;19(12):3165–3175.
   PubMed Web of Science ®Google Scholar
• Dix AR, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999;100(1–2): 216–232. Epub 2000/ 03/01.PubMed PMID: 10695732.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–5480. Epub 2011/ 07/09. doi: 10.1158/1078-0432.CCR-11-0774. PubMed PMID: 21737504; PubMed Central PMCID: PMCPMC3156964.
   PubMed Web of Science ®Google Scholar
• Chongsathidkiet P, Jackson C, Koyama S, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9):1459–1468. Epub 2018/08/15. 10.1038/s41591-018-0135-2. PubMed PMID: 30104766; PubMed Central PMCID: PMCPMC6129206.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. Epub 2015/04/22. PubMed PMID: 25891173.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–1833. Epub 2016/10/11. PubMed PMID: 27718847.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–1813. Epub 2015/09/26. PubMed PMID: 26406148; PubMed Central PMCID: PMCPMC5719487.
   PubMed Web of Science ®Google Scholar
• Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–349. Epub 2013/03/07. PubMed PMID: 23462419; PubMed Central PMCID: PMCPMC3963403.
   PubMed Web of Science ®Google Scholar
• Genoud V, Marinari E, Nikolaev SI, et al. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology. 2018;7(12):e1501137. Epub 2018/12/14. PubMed PMID: 30524896; PubMed Central PMCID: PMCPMC6279422.
   PubMed Web of Science ®Google Scholar
• Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. Neuro Oncol. 2017;19(3):454–456. Epub 2017/01/01. PubMed PMID: 28039369; PubMed Central PMCID: PMCPMC5464329.
   PubMed Web of Science ®Google Scholar
• Viale G, Trapani D, Curigliano G. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. Biomed Res Int2017;2017:4719194. Epub 2017/08/05. PubMed PMID: 28770222; PubMed Central PMCID: PMCPMC5523547.
   PubMed Web of Science ®Google Scholar
• Kamiya-Matsuoka C, Metrus NR, Shaw KR, et al. The natural course of hypermutator gliomas. J Clin Oncol. 2018;36(15_suppl):2014.
   Web of Science ®Google Scholar
• Sampson JH, Vlahovic G, Sahebjam S, et al. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. J Clin Oncol. 2015;33(15_suppl):3010.
   Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20(5):674–686. Epub 2017/ 11/07. PubMed PMID: 29106665; PubMed Central PMCID: PMCPMC5892140.
   PubMed Web of Science ®Google Scholar
• Lim M, Omuro A, Vlahovic G, et al. 325ONivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM). Ann Oncol. 2017;28(suppl_5):mdx366–mdx.
   Google Scholar
• Reardon DA, Nayak L, Peters KB, et al. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol. 2018;36(15_suppl):2006.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–486. Epub 2019/02/12. 10.1038/s41591-018-0337-7. PubMed PMID: 30742122; PubMed Central PMCID: PMCPMC6408961.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–9553. Epub 2005/10/18. PubMed PMID: 16227604; PubMed Central PMCID: PMCPMC1265804.
   PubMed Web of Science ®Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Epub 2015/09/24. doi: 10.1056/NEJMc1509660. PubMed PMID: 26398076;373(13):1270–1271.
   PubMed Web of Science ®Google Scholar
• Zhai L, Kl L, Chang AL, et al. The role of IDO in brain tumor immunotherapy. J Neurooncol. 2015;123(3):395–403. Epub 2014/ 12/19. PubMed PMID: 25519303; PubMed Central PMCID: PMCPMC4641522.
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Balyasnikova IV, Chang AL, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18(22):6110–6121. Epub 2012/08/31. 10.1158/1078-0432.CCR-12-2130. PubMed PMID: 22932670; PubMed Central PMCID: PMCPMC3500434.
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9(10):1069–1077. Epub 2002/09/17. doi:. PubMed PMID: 12232795.
   PubMed Web of Science ®Google Scholar
• Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol2011;344:269–278. Epub 2010/ 11/19. PubMed PMID: 21086108; PubMed Central PMCID: PMCPMC4696019.
   PubMed Web of Science ®Google Scholar
• Harris-Bookman S, Mathios D, Martin AM, et al. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer. 2018;143(12):3201–3208. Epub 2018/09/25. PubMed PMID: 30248181.
   PubMed Web of Science ®Google Scholar
• Pollok KE, Kim YJ, Zhou Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150(3):771–781. Epub 1993/02/01. PubMed PMID: 7678621.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol2011;350:1–15. Epub 2010/ 08/12. PubMed PMID: 20700701.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501. Epub 2016/02/18. PubMed PMID: 26883990; PubMed Central PMCID: PMCPMC4757784.
   PubMed Web of Science ®Google Scholar
• Kim JE, Patel MA, Mangraviti A, et al. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res. 2017;23(1):124–136. Epub 2016/07/01. 10.1158/1078-0432.CCR-15-1535. PubMed PMID: 27358487; PubMed Central PMCID: PMCPMC5735836.
   PubMed Web of Science ®Google Scholar
• Li G, Wang Z, Zhang C, et al. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. Oncoimmunology. 2017;6(8):e1328339. Epub 2017/09/19. PubMed PMID: 28919992; PubMed Central PMCID: PMCPMC5593703.
   PubMed Web of Science ®Google Scholar
• Jiang H, McCormick F, Lang FF, et al. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther. 2006;6(5):697–708. Epub 2006/06/09. PubMed PMID: 16759161.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gomez-Manzano C, Rivera-Molina Y, et al. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol2015;13:33–39. Epub 2015/ 04/13. PubMed PMID: 25863716; PubMed Central PMCID: PMCPMC4550502.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. Epub 2011/ 03/08. PubMed PMID: 21376230.
   PubMed Web of Science ®Google Scholar
• Jiang H, Fueyo J. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology. 2014;3(7):e947872. Epub 2014/ 01/01. PubMed PMID: 25954598; PubMed Central PMCID: PMCPMC4355947.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol. 2018;36(14):1419–1427. Epub 2018/ 02/13. PubMed PMID: 29432077; PubMed Central PMCID: PMCPMC6075856.
   PubMed Web of Science ®Google Scholar
• Brown MC, Holl EK, Boczkowski D, et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med. 2017;9(408). Epub 2017/09/22. doi: 10.1126/scitranslmed.aan4220. PubMed PMID: 28931654; PubMed Central PMCID: PMCPMC6034685.
   Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018;379(2):150–161. Epub 2018/06/27. PubMed PMID: 29943666; PubMed Central PMCID: PMCPMC6065102.
   PubMed Web of Science ®Google Scholar
• Kmiecik J, Zimmer J, Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol. 2014;116(1):1–9. Epub 2013/ 10/03. PubMed PMID: 24085644; PubMed Central PMCID: PMCPMC3889498.
   PubMed Web of Science ®Google Scholar
• Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116(7):1035–1044. Epub 2010/05/05. PubMed PMID: 20439624; PubMed Central PMCID: PMCPMC2938125.
   PubMed Web of Science ®Google Scholar
• Maher J. Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Curr Gene Ther. 2014;14(1): 35–43. Epub 2013/ 12/25.PubMed PMID: 24365143.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016;375(26):2561–2569. Epub 2016/12/29. PubMed PMID: 28029927; PubMed Central PMCID: PMCPMC5390684.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399). Epub 2017/07/21. doi: 10.1126/scitranslmed.aaa0984. PubMed PMID: 28724573; PubMed Central PMCID: PMCPMC5762203.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474–485. Epub 2010/01/14. 10.1158/1078-0432.CCR-09-1322. PubMed PMID: 20068073; PubMed Central PMCID: PMCPMC3682507.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Desai AS, Linette GP, et al. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018;20(11):1429–1438. Epub 2018/ 03/07. PubMed PMID: 29509936; PubMed Central PMCID: PMCPMC6176794.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636–5646. Epub 2013/07/23. 10.1158/1078-0432.CCR-13-0458. PubMed PMID: 23873688.
   PubMed Web of Science ®Google Scholar
• Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–1615. Epub 2010/ 12/08. 10.1158/1078-0432.CCR-10-2563. PubMed PMID: 21135147; PubMed Central PMCID: PMCPMC3071163.
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973–4979. Epub 2004/07/17. PubMed PMID: 15256471.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89(7):1172–1179. Epub 2003/ 10/02. PubMed PMID: 14520441; PubMed Central PMCID: PMCPMC2394324.
   PubMed Web of Science ®Google Scholar
• Antonios JP, Soto H, Everson RG, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1(10). Epub 2016/07/28. 10.1172/jci.insight.87059. PubMed PMID: 27453950; PubMed Central PMCID: PMCPMC4951098.
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–1272. Epub 2013/09/24. PubMed PMID: 24056773; PubMed Central PMCID: PMCPMC3840724.
   PubMed Web of Science ®Google Scholar
• Butowski N, Colman H, De Groot JF, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18(4):557–564. Epub 2015/ 10/10. PubMed PMID: 26449250; PubMed Central PMCID: PMCPMC4799682.
   PubMed Web of Science ®Google Scholar
• Han J, Alvarez-Breckenridge CA, Wang QE, et al. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res. 2015 Epub 2015/06/06. PubMed PMID: 26045979; PubMed Central PMCID: PMCPMC4449428;5(3):945–955.
   PubMed Web of Science ®Google Scholar
• Yamada N, Kato M, Yamashita H, et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer. 1995;62(4):386–392. Epub 1995/08/09. PubMed PMID: 7635563.
   PubMed Web of Science ®Google Scholar
• Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132–142. Epub 2010/ 10/29. PubMed PMID: 20980335; PubMed Central PMCID: PMCPMC3018908.
   PubMed Web of Science ®Google Scholar
• Hollander MWd, Bensch F, Glaudemans AWJM, et al. 89zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients. J Clin Oncol. 2013;31(15_suppl):2050.
   Google Scholar
• Rodon J, Carducci MA, Sepulveda-Sanchez JM, et al. First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. 2015;21(3):553–560. Epub 2014/11/27. PubMed PMID: 25424852; PubMed Central PMCID: PMCPMC4337847.
   PubMed Web of Science ®Google Scholar
• Roy LO, Poirier MB, Fortin D. Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors. Int J Mol Sci. 2018;19(4):1113. Epub 2018/04/13. PubMed PMID: 29642484; PubMed Central PMCID: PMCPMC5979513.
   Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. Epub 2009/ 11/26. 10.1158/1078-0432.CCR-09-1624. PubMed PMID: 19934295.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175. Epub 2010/ 06/03. PubMed PMID: 20516446; PubMed Central PMCID: PMCPMC4834717.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–e42. Epub 2015/ 11/08. PubMed PMID: 26545842; PubMed Central PMCID: PMCPMC4638131.
   PubMedGoogle Scholar
• Colen R, Hassan A, Elshafeey N, et al. NIMG-03. RADIOMIC TEXTURE ANALYSIS TO PREDICT RESPONSE TO IMMUNOTHERAPY. Neuro Oncol. 2018;20(suppl_6):vi176–vi.
   Google Scholar
• Frey B, Rubner Y, Wunderlich R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr Med Chem. 2012;19(12):1751–1764. Epub 2012/03/15.PubMed PMID: 22414083.
   PubMed Web of Science ®Google Scholar
• Hutchinson L. Immunotherapy: exploiting mismatch repair in GBM. Nat Rev Clin Oncol. 2016;13(5):264. Epub 2016/ 04/14. PubMed PMID: 27071348.
   PubMedGoogle Scholar
• Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15(1):927–943. Epub 2014/01/18. doi:. PubMed PMID: 24434638; PubMed Central PMCID: PMCPMC3907847.
   PubMed Web of Science ®Google Scholar
• Yovino S, Kleinberg L, Grossman SA, et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013;31(2):140–144. Epub 2013/02/01. PubMed PMID: 23362951; PubMed Central PMCID: PMCPMC3991115.
   PubMed Web of Science ®Google Scholar
• Maxwell R, Jackson CM, Lim M. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Curr Treat Options Oncol. 2017;18(8):51.
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MC, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016 Dec;6:1382–1399. Epub 2016/09/25. PubMed PMID: 27663893.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, et al. Publisher Correction: neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(12):1942. Epub 2018/ 10/27. PubMed PMID: 30361511.
   PubMed Web of Science ®Google Scholar
• Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018 Nov;24:1655–1661. Epub 2018/10/10. 10.1038/s41591-018-0198-0. PubMed PMID: 30297911.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18:1373–1385. Epub 2017/ 08/29. PubMed PMID: 28844499.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33(28):3193–3198. Epub 2015/08/19. PubMed PMID: 26282644; PubMed Central PMCID: PMCPMC5087335. Available from: www.jco.org. Author contributions are found at the end of this article.
   PubMed Web of Science ®Google Scholar
• Santini FC, Rizvi H, Wilkins O, et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. 2017;35(15_suppl):9012.
   Google Scholar
• Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–2878. PubMed PMID: 30125216.
   PubMed Web of Science ®Google Scholar
• Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139(Pt 5):1458–1471. Epub 2016/03/30. PubMed PMID: 27020328; PubMed Central PMCID: PMCPMC5006251.
   PubMed Web of Science ®Google Scholar
• Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–1095. Epub 2012/ 10/12. PubMed PMID: 23051966.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. Epub 2016/ 01/15. PubMed PMID: 26765102.
   PubMed Web of Science ®Google Scholar
• Huang B, Zhang H, Gu L, et al. Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res. 2017;2017:3597613. Epub 2017/03/17. PubMed PMID: 28299344; PubMed Central PMCID: PMCPMC5337363.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. Epub 2014/ 02/21. PubMed PMID: 24553385; PubMed Central PMCID: PMCPMC4017867.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. Epub 2015/11/12. PubMed PMID: 26554728; PubMed Central PMCID: PMCPMC5426516.
   PubMed Web of Science ®Google Scholar
• Wang Y, Springer S, Zhang M, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112(31):9704–9709. Epub 2015/07/22. PubMed PMID: 26195750; PubMed Central PMCID: PMCPMC4534284.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199. Epub 2014/11/20. PubMed PMID: 25409260; PubMed Central PMCID: PMCPMC4315319.
   PubMed Web of Science ®Google Scholar
• Hodges TR, Ott M, Xiu J, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017;19(8):1047–1057. Epub 2017/ 04/04. PubMed PMID: 28371827; PubMed Central PMCID: PMCPMC5570198.
   PubMed Web of Science ®Google Scholar
• Leone P, Shin EC, Perosa F, et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105(16):1172–1187. Epub 2013/ 07/16. PubMed PMID: 23852952.
   PubMedGoogle Scholar
• Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90(6):1115–1124. Epub 1999/06/01. PubMed PMID: 10350260.
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008;10(1):10–18. Epub 2007/ 10/24. doi: 10.1215/15228517-2007-035. PubMed PMID: 17951512; PubMed Central PMCID: PMCPMC2600830.
   PubMed Web of Science ®Google Scholar
• Batich KA, Reap EA, Archer GE, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clin Cancer Res. 2017;23(8):1898–1909. Epub 2017/04/16. PubMed PMID: 28411277; PubMed Central PMCID: PMCPMC5559300.
   PubMed Web of Science ®Google Scholar
• Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015;3:4. Epub 2015/04/08. PubMed PMID: 25849072; PubMed Central PMCID: PMCPMC4359524.
   PubMed Web of Science ®Google Scholar
• Rampling R, Peoples S, Mulholland PJ, et al. A cancer research uk first time in human phase I trial of ima950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res. 2016;22(19):4776–4785. Epub 2016/ 05/27. 10.1158/1078-0432.CCR-16-0506. PubMed PMID: 27225692; PubMed Central PMCID: PMCPMC5026298.
   PubMed Web of Science ®Google Scholar
• Migliorini D, Dutoit V, Allard M, et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol. 2019. Epub 2019/02/13. doi: 10.1093/neuonc/noz040. PubMed PMID: 30753611.
   PubMed Web of Science ®Google Scholar
• Wick W, Dietrich P-Y, Kuttruff S, et al. GAPVAC-101: first-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. J Clin Oncol. 2018;36(15_suppl):2000.
   Web of Science ®Google Scholar
• Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2018. DOI:10.1038/s41586-018-0810-y.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49. Epub 2011/01/08. PubMed PMID: 21212348; PubMed Central PMCID: PMCPMC3089969.
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Tsuboi K, Saijo K, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004;24(3b):1861–1871. Epub 2004/07/28.PubMed PMID: 15274367.
   PubMed Web of Science ®Google Scholar
• Mathios D, Park CK, Marcus WD, et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer. 2016;138(1):187–194. Epub 2015/ 07/16. PubMed PMID: 26174883; PubMed Central PMCID: PMCPMC4696021.
   PubMed Web of Science ®Google Scholar
• Elakkad A, Kotrotsou A, Kumar AM, et al. 100 toward the co-clinical glioblastoma treatment paradigm—radiomic machine learning identifies glioblastoma gene expression in patients and corresponding xenograft tumor models. Neurosurgery. 2018;65(CN_suppl_1):80.
   PubMedGoogle Scholar
• Bae S, Choi YS, Ahn SS, et al. Radiomic MRI Phenotyping of Glioblastoma: improving Survival Prediction. Radiology. 2018;289(3):797–806. PubMed PMID: 30252635.
   PubMed Web of Science ®Google Scholar
• Kjaergaard J, Tanaka J, Kim JA, et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19): 5514–5521. Epub 2000/10/18.PubMed PMID: 11034096.
   PubMed Web of Science ®Google Scholar
• Ohkuri T, Ghosh A, Kosaka A, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014;2(12):1199–1208. Epub 2014/10/11. PubMed PMID: 25300859; PubMed Central PMCID: PMCPMC4258479.
   PubMed Web of Science ®Google Scholar
• Chang N, Ahn SH, Kong DS, et al. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. Mol Cell Endocrinol2017;451:53–65. Epub 2017/01/17. PubMed PMID: 28089821.
   PubMed Web of Science ®Google Scholar
• Jensen KV, Cseh O, Aman A, et al. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One. 2017;12(12):e0189670. Epub 2017/12/19. PubMed PMID: 29253028; PubMed Central PMCID: PMCPMC5734728.
   PubMed Web of Science ®Google Scholar